about
The latest mania: selling bipolar disorder.Schizophrenia: a multisystem disease?Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyMortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control studyGeneral medical problems of incarcerated persons with severe and persistent mental illness: a population-based study.Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.Incentives and barriers to lifestyle interventions for people with severe mental illness: a narrative synthesis of quantitative, qualitative and mixed methods studies.Differential cardiac effects of aerobic interval training versus moderate continuous training in a patient with schizophrenia: a case report.Mortality in schizophrenia: a measurable clinical endpointAre there modifiable risk factors which will reduce the excess mortality in schizophrenia?New roles for pharmacists in community mental health care: a narrative review.Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ӔSOP first-episode cohort.Antipsychotic Maintenance Treatment: Time to Rethink?Systematic computerised cardiovascular health screening for people with severe mental illnessPhysical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Factors associated with non evidence-based prescribing of antipsychoticsTranscriptome alterations of mitochondrial and coagulation function in schizophrenia by cortical sequencing analysis.Mortality among long-stay patients with schizophrenia during the setting-up of community facilities under the Yuli model.Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorPolypharmacy or medication washout: an old tool revisitedTen-Year Outcomes of First-Episode Psychoses in the MRC ÆSOP-10 Study.The association between antipsychotic agents and the risk of myocardial infarction: a systematic review.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Safety and tolerability of antipsychotic polypharmacy.Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England.Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients.Psychometric characteristics of the "General Oral Health Assessment Index (GOHAI) » in a French representative sample of patients with schizophreniaCardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.Mortality among patients with schizophrenia and vocational rehabilitation program services under Taiwan's psychiatric care reform.An outcome measure in schizophrenia: mortality.Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortalityLong-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.Kraepelin's dichotomy is true: contrasting brain dysfunction at the extremes of human growth and maturation. Excitability, the fundamental property of nervous tissue, is affected.Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services.Prevalence of metabolic syndrome and its association with depression in patients with schizophreniaPredictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
P2860
Q21090149-E14CD6A9-A002-474F-90E1-FD7CA31362EBQ24633845-707E43E4-C100-4640-875E-6276D2AD3960Q27028197-BBF732B1-B663-4A87-B2E6-AD0C18B44F8EQ30485065-9C75E3D3-70FA-41F8-88A4-5D634E878FC9Q30572656-0E5B57FE-1EDF-42AD-922C-AC955957BBC7Q30792325-2CDCA572-1B31-4206-AF57-7399E439F07AQ30993822-9DF3B025-D416-4338-AA74-213A22BC7C0DQ33693324-30A847F1-298C-43F8-AE06-830AC0192074Q33818732-EC73C3DC-2FB0-4CA2-85C9-90748D0E5168Q33821289-71C6E9A3-C937-4738-9A59-707F06BE4224Q34106281-2B4CE9FC-B5EB-4021-860F-179055E74956Q34183484-FD3AABBE-CF03-4DBE-A34C-C4CD067D12B4Q34183495-C9A2482F-2D4F-48A6-8692-86080F9592F8Q34412191-924AD44C-527C-4AA4-8CEE-DD0219A33511Q34440708-3488285F-FD78-4749-AC2B-0C3D2CB63F61Q34488215-D551B2BB-8DBE-4895-B544-6B87B01C6068Q34589590-6255A2E5-730E-444F-B5D3-9ECDE78CADD8Q34623350-E8E6025E-67EE-4F55-BC8C-AC32E826C7B5Q34642808-24CF2792-5A43-4D18-8CED-ED2E9B94C799Q34913157-8B440653-B837-429C-AE28-319A8724B699Q35136374-CF47D447-64C3-4D39-8FBF-04276BC4321CQ35175610-A2EA6360-6969-452C-8F53-8BDD12E890D7Q35548200-E781CAE2-F3F6-496B-9D49-05342FC8D8CEQ35552486-D4F71773-E340-4E85-9F79-9E1FC42866EEQ35629735-47D500A5-1EE2-42DC-834D-2D1E49A40127Q36057820-42C038EC-6D63-4579-99BE-79BFA25EB344Q36062421-09E61E45-B810-4FF4-8A7A-1EB2FB3438E8Q36159743-5CDADDD1-D4A7-4773-ADCD-8D1DCB2D8D7BQ36303695-59177C58-22C5-4CC2-B554-809E0FD16AB4Q36343850-919C3B01-0D59-43A7-BC93-6AA95871E5B8Q36714070-536A3F60-622E-4783-AAF8-8FE1F354CB63Q36790443-6693C75B-E08E-48AD-B537-4DEFD756F5E7Q36795525-0C03F756-CDDC-4070-A332-53F438134B69Q36853303-E79B777A-7C68-44D8-AEF3-A69F797BFBD7Q36905083-3C4513DE-1069-40F2-A385-25FAEE4518BEQ36948432-8C731E5F-2096-4EA2-B6D7-1E23AA2F815CQ36957061-BB942A3D-720C-42C6-9533-CD7BD530D6DFQ37007481-D3C2A4AE-F83F-4BF9-9C49-3E863257ED7BQ37042072-2721E35E-642B-4B67-8B64-E77191951FDBQ37137001-085F911B-CCC9-429E-8299-409ECA29764C
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Schizophrenia, neuroleptic medication and mortality.
@ast
Schizophrenia, neuroleptic medication and mortality.
@en
Schizophrenia, neuroleptic medication and mortality.
@nl
type
label
Schizophrenia, neuroleptic medication and mortality.
@ast
Schizophrenia, neuroleptic medication and mortality.
@en
Schizophrenia, neuroleptic medication and mortality.
@nl
prefLabel
Schizophrenia, neuroleptic medication and mortality.
@ast
Schizophrenia, neuroleptic medication and mortality.
@en
Schizophrenia, neuroleptic medication and mortality.
@nl
P2093
P356
P1476
Schizophrenia, neuroleptic medication and mortality.
@en
P2093
Arpo Aromaa
Matti Joukamaa
Paul Knekt
Raimo Raitasalo
Ville Lehtinen
P304
P356
10.1192/BJP.188.2.122
P407
P577
2006-02-01T00:00:00Z